Infection on a Chip

How Bioelectronics is Profiling Viral Variants

SARS-CoV-2 Viral Variants Bioelectronics Pandemic Preparedness

The Race Against Viral Mutation

In the relentless battle between humans and viruses, our greatest challenge has been the speed of the enemy. RNA viruses, like SARS-CoV-2, mutate at a breathtaking pace, constantly spawning new variants that can evade vaccines and redefine the course of a pandemic 1 3 .

Traditional Detection

PCR tests identify viruses but reveal little about their infectivity or evolutionary trajectory 1 3 .

Bioelectronic Solution

The infection-on-a-chip platform profiles viral variants by watching them in the act of infection 1 7 .

How Viruses Invade a Cell

For an enveloped virus like SARS-CoV-2, infection is a multi-stage breaking and entering process, all orchestrated by the now-infamous Spike protein that protrudes from its surface 1 9 .

The Early Pathway (Direct Assault)

When the host cell has TMPRSS2 on its surface, the virus fuses directly with the cell's outer membrane after Spike protein binds to ACE2 1 3 .

Step 1: Spike protein binds to ACE2 receptor
Step 2: TMPRSS2 cleaves Spike protein
Step 3: Immediate fusion with cell membrane
Step 4: Viral genome release into cell
The Late Pathway (Stealth Entry)

When TMPRSS2 is absent, the virus is swallowed whole via endocytosis and fuses inside the endosome with help from Cathepsin L (CatL) 1 3 .

Step 1: Spike protein binds to ACE2 receptor
Step 2: Virus engulfed via endocytosis
Step 3: Low pH and CatL trigger fusion
Step 4: Viral genome release from endosome

The Infection-on-a-Chip Platform

Taking inspiration from biology, scientists built a simplified, controllable model of viral entry with four key design pillars 1 :

Membrane Presentation
Environmental Control
Biocompatible Scaffold
Quantifiable Readout

Building an Artificial Cell Membrane

The heart of the device is a Supported Lipid Bilayer (SLB) - an artificial cell membrane containing ACE2 receptors and TMPRSS2 proteases 1 3 .

To model the virus, researchers use Viral Pseudoparticles (VPPs) - non-infectious particles with authentic Spike proteins 1 .

The sensor uses a transparent, conductive PEDOT:PSS polymer that acts as both support and electrode, detecting changes via electrochemical impedance spectroscopy (EIS) 1 9 .

Bioelectronic Platform Schematic
VPP with Spike Protein
SLB with ACE2/TMPRSS2
PEDOT:PSS Electrode
Sensor Base

The platform recreates viral entry on a miniature, cell-free stage 1 9 .

A Closer Look: Profiling Omicron Subvariants

To test the platform, scientists compared the fusogenicity of Omicron subvariants BA.1 and BA.4 1 3 .

Methodology: Step-by-Step Profile
Platform Setup: SLBs prepared with ACE2 and TMPRSS2 (early pathway) or ACE2 only (late pathway) 1 .
Variant Introduction: VPPs with WH1, BA.1, and BA.4 Spike proteins introduced separately 1 .
Pathway Activation: Early pathway triggered by TMPRSS2; late pathway by acidic buffer with CatL 1 .
Electrical Monitoring: EIS continuously monitored binding and fusion events 1 .
Results and Analysis

The platform successfully generated distinct electrical signals and revealed markedly different fusion signatures between variants 1 .

Fusion Efficiency Comparison
WH1 (Original) Baseline
Omicron BA.1 Reduced
Omicron BA.4 Further Reduced

Relative fusion efficiency in the late pathway compared to WH1 1

Variant Fusion Characteristics
Variant Fusion Efficiency (Late Pathway) Fusion Characteristics (vs. WH1)
WH1 (Original) Baseline Used both early and late pathways effectively 1
Omicron BA.1 Reduced Showed a preference for the late entry pathway, with less efficient fusion 1
Omicron BA.4 Further Reduced Exhibited even lower fusion efficiency compared to BA.1 in the late pathway 1
Platform Measurement Capabilities
Measurement Type What It Reveals Application in Variant Profiling
Binding Signal Strength of initial virus attachment to ACE2 receptor 1 Indicates how readily a variant can latch onto host cells
Fusion Signal Success and efficiency of membrane merger post-binding 1 Reveals the variant's core ability to complete the infection process
Signal Kinetics The speed and progression of the entry process 1 Can identify if a variant has a slower or faster entry mechanism

The Scientist's Toolkit

Building and using this bioelectronic platform requires a suite of specialized research reagents and materials.

Research Reagent / Material Function in the Experiment
Viral Pseudoparticles (VPPs) Non-infectious virus mimics decorated with specific Spike proteins, used to safely model viral entry 1
Supported Lipid Bilayer (SLB) An artificial cell membrane assembled on a sensor surface, serving as the host cell mimic 1 3
Cell Membrane Blebs Vesicles containing native host cell proteins (ACE2, TMPRSS2), integrated into SLBs to provide authentic receptors 1
PEDOT:PSS Electrode A conductive, biocompatible polymer support that hosts the SLB and transduces biological events into electrical signals 1
Proteases (TMPRSS2, CatL) Enzymes that cleave the Spike protein, acting as the molecular triggers for membrane fusion in their respective pathways 1
Electrochemical Impedance Spectroscopy (EIS) The analytical technique that measures changes in electrical impedance at the electrode surface to monitor binding and fusion in real-time 1 9

A New Frontier in Pandemic Preparedness

The infection-on-a-chip platform marks a significant leap forward from simply detecting a pathogen to functionally understanding its infectivity potential.

Drug Screening

Can be used to screen the effectiveness of antiviral drugs by testing whether they can block binding or fusion on the platform 1 9 .

Early Warning

Ability to quickly profile fusogenicity of new variants could provide early warning of strains with enhanced infectivity 1 9 .

Future Applications

While SARS-CoV-2 served as the prototype, the platform is designed to be adaptable. In the future, this same approach could be extended to other enveloped viruses—from influenza to potential pandemic pathogens yet unknown—ensuring that we are better equipped, faster, and smarter when the next viral threat emerges 1 .

Influenza HIV Ebola Respiratory Syncytial Virus Emerging Pathogens

References

References